Venture Life Group (VLG)

Sector:

Health Care

Index:

FTSE AIM All-Share

 43.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 49.00p
  • 52 Week Low: 28.00p
  • Currency: UK Pounds
  • Shares Issued: 127.05m
  • Volume: 253,790
  • Market Cap: £54.63m

Venture Life joins Covid-19 mouthwash trial

By Josh White

Date: Monday 24 Aug 2020

LONDON (ShareCast) - (Sharecast News) - Self-care products company Venture Life announced its involvement in a UK-led clinical trial on Covid-19 patients on Monday, in partnership with Cardiff University.
The AIM-traded firm had announced its support for further research into the idea that using mouthwash could reduce the transmission of enveloped viruses such as Covid-19 on 15 May.

It said on Monday that the new independent, multi-centre clinical study, which was being led by Professor David Thomas at Cardiff, would investigate the possibility that using over-the-counter mouthwashes could help to reduce the viral load, and thus the transmission of Covid-19 in the mouth.

Venture Life said it was "delighted" to confirm that its mouthwash brand 'Dentyl' would be involved in the UK clinical trial.

It said a literature review of previous research led by Professor Valerie O'Donnell at Cardiff, and expert input from a group of virologists, microbiocide experts, lipid specialists and healthcare experts from the universities of Cardiff, Nottingham, Ottawa and Barcelona, published in May, suggested the possibility that certain mouthwashes could be used to help reduce transmission of enveloped viruses such as SARS-CoV2, but that more research was needed to test the idea.

The review concluded that cetylpyridinium chloride (CPC) could be effective in that respect.

Venture Life said its Dentyl mouthwash, which is currently sold in the UK and 11 other countries, contains CPC as its main active ingredient.

The clinical study entitled 'the measurement of mouthwash antiviral activity against Covid-19' would be starting this month, and was expected to last for 12 weeks.

It would be a multi-centre study, and would recruit patients currently in hospital with Covid-19, beginning at Cardiff Hospital.

"We are the only mouthwash manufacturer to be involved in the Cardiff University clinical study on Covid-19 patients; we are delighted to support this independent study to further explore the initial findings that CPC may reduce the viral load and therefore the possible transmission of Covid-19," said chief executive officer Jerry Randall.

"Our Dentyl mouthwash, which uses CPC as its main antibacterial agent, has been developed by dentists and is recommended by dentists to reduce plaque in the mouth, and is very effective at this.

"We are excited at the prospect that this long standing, well known mouthwash product could help in the fight against Covid-19."

At 1512 BST, shares in Venture Life Group were up 7.51% at 93p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

VLG Market Data

Currency UK Pounds
Share Price 43.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 49.00p
52 Week Low 28.00p
Volume 253,790
Shares Issued 127.05m
Market Cap £54.63m

VLG Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
66.19% above the market average66.19% above the market average66.19% above the market average66.19% above the market average66.19% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
82.03% above the market average82.03% above the market average82.03% above the market average82.03% above the market average82.03% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Income Not Available
Growth
38.43% above the market average38.43% above the market average38.43% above the market average38.43% above the market average38.43% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average

VLG Dividends

  Latest Previous
  Final Interim
Ex-Div 24-May-18 n/a
Paid 22-Jun-18 n/a
Amount 0.040p 0.000p

Trades for 31-Oct-2024

Time Volume / Share Price
16:42 46,729 @ 43.00p
16:42 3,271 @ 43.00p
16:35 68,000 @ 43.00p
16:35 68,000 @ 43.00p
16:29 10,000 @ 42.56p

VLG Key Personnel

CEO Jerry Randall
CFO Daniel Wells

Top of Page